메뉴 건너뛰기
Journal of Clinical Oncology
Volumn 23, Issue 9, 2005, Pages 2113-
Inhibition of angiogenesis: Thalidomide or low-molecular-weight heparin? [11]
Author keywords

[No Author keywords available]
Indexed keywords

DALTEPARIN; DOCETAXEL; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; THALIDOMIDE; ANGIOGENESIS INHIBITOR; ANTICOAGULANT AGENT;
EID: 15744375765     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.245     Document Type: Letter
Times cited : (12)
References (7)
  • 1
    • 4344682179 scopus 로고    scopus 로고
    • Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer
    • Dahut WL, Gulley JL, Arlen PM, et al: Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22:2532-2539, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 2532-2539
    • Dahut, W.L.1    Gulley, J.L.2    Arlen, P.M.3
  • 2
    • 0033027368 scopus 로고    scopus 로고
    • Angiogenesis in urological malignancy: Prognostic indicator and therapeutic target
    • Jones A, Fujiyama C: Angiogenesis in urological malignancy: Prognostic indicator and therapeutic target. BJU Int 83:535-555, 1999
    • (1999) BJU Int , vol.83 , pp. 535-555
    • Jones, A.1    Fujiyama, C.2
  • 3
    • 0035691274 scopus 로고    scopus 로고
    • Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer
    • Lissbrant IF, Lissbrant E, Damber J, et al: Blood vessels are regulators of growth, diagnostic markers and therapeutic targets in prostate cancer. Scand J Urol Nephrol 35:437-452, 2001
    • (2001) Scand J Urol Nephrol , vol.35 , pp. 437-452
    • Lissbrant, I.F.1    Lissbrant, E.2    Damber, J.3
  • 4
    • 0022366074 scopus 로고
    • A new class of steroids inhibits angiogenesis in the presence of heparin or heparin fragment
    • Crum R, Szabo S, Folkman J: A new class of steroids inhibits angiogenesis in the presence of heparin or heparin fragment. Science 230:1375-1378, 1985
    • (1985) Science , vol.230 , pp. 1375-1378
    • Crum, R.1    Szabo, S.2    Folkman, J.3
  • 5
    • 0020572581 scopus 로고
    • Angiogenesis inhibition and tumor regression caused by heparin or heparin fragment in the presence of cortisone
    • Folkman J, Langer R, Linhard RJ, et al: Angiogenesis inhibition and tumor regression caused by heparin or heparin fragment in the presence of cortisone. Science 221:719-725, 1983
    • (1983) Science , vol.221 , pp. 719-725
    • Folkman, J.1    Langer, R.2    Linhard, R.J.3
  • 6
    • 12844289104 scopus 로고    scopus 로고
    • A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer
    • Altinbas M, Coskun HS, Er O, et al: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost 2:1266-1271, 2004
    • (2004) J Thromb Haemost , vol.2 , pp. 1266-1271
    • Altinbas, M.1    Coskun, H.S.2    Er, O.3
  • 7
    • 3042704507 scopus 로고    scopus 로고
    • Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS)
    • Kakkar AK, Levine MN, Kadziola Z, et al: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: The fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol 22:1944-1948, 2004
    • (2004) J Clin Oncol , vol.22 , pp. 1944-1948
    • Kakkar, A.K.1    Levine, M.N.2    Kadziola, Z.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.